Smith & Nephew

SNN

Market cap $12.6B

Veeva Systems expands its medtech reach as Smith+Nephew adopts Veeva Quality Cloud to modernize global quality operations and training.

Smith & Nephew plc (SNN) Q1 2026 Sales/Trading Call Transcript

Medical products maker ​Smith+Nephew posted ‌a 3.1% rise ​in ​first-quarter underlying revenue on ⁠Wednesday, ​helped by ​strong sports medicine and wound ​management ​performance, and kept ‌its ⁠annual outlook unchanged while announcing ​a $500 ​million ⁠share buyback.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound Management Association (EWMA) Conference, Bremen between 6-8 May 2026.

Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?

Smith+Nephew's CARTIHEAL implant shows superior 5-year outcomes vs. standard care, with a new CPT code set to boost adoption and expand cartilage repair reach.

Smith + Nephew launches ALLEVYN COMPLETE CARE foam dressing for wound management, expanding its Advanced Wound Management portfolio.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, recently announced the launch of ALLEVYN♢ COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed by a portfolio of strong scientific data and clinical evidence.

Smith+Nephew announces it will feature handheld robotics during the American Academy of Orthopedic Surgeons (AAOS) Annual meeting in New Orleans this week.

Uniting the most advanced technologies for biomechanical repair and biological augmentation  Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase its unrivalled portfolio for rotator cuff repair (RCR) during the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans this week. RCR is a growing market segment with approximately 500,000 procedures performed annually in the US,1 yet still experiencing 20–40%2 structural failure rates using traditional surgical techniques.